Тёмный

How to Appraise a Clinical Trial - Part 2 

Strong Medicine
Подписаться 700 тыс.
Просмотров 25 тыс.
50% 1

An overview of how to read and critically evaluate a clinical trial, prior to applying the information to your patient. Included is a discussion of the importance of randomization, controls, blinding, allocation concealment, proper sample size, and more.
For a printable summary of this series on appraising a clinical trial, see the relevant pdf located here: drive.google.com/drive/folder...

Опубликовано:

 

5 авг 2024

Поделиться:

Ссылка:

Скачать:

Готовим ссылку...

Добавить в:

Мой плейлист
Посмотреть позже
Комментарии : 24   
@MahdiAldaini
@MahdiAldaini 2 года назад
Im so happy to have found you sir. What an amazing video. I just learned so much. You are positively impacting the life of so many doctors and patients. Thanks you.
@StrongMed
@StrongMed 2 года назад
Thank you for the kind words!
@the1saul1
@the1saul1 7 лет назад
This is fantastic (as usual)! Comprehensive and clear. Keep up the good work!
@MsP0624
@MsP0624 Год назад
Your videos are so clear and helpful. Thank you.
@zannatul23
@zannatul23 5 лет назад
Dear Sir, thank you so much for this video. Very informative and helpful. Really appreciate it.
@dhashanisivaratnam2126
@dhashanisivaratnam2126 6 лет назад
AWESOME !! Thank you.
@pelesaifostina8002
@pelesaifostina8002 Год назад
Thank you so much God bless you
@lizbethmcewan
@lizbethmcewan 7 лет назад
Thank you.
@MrJukamada
@MrJukamada 2 года назад
This is good!
@pochola4550
@pochola4550 4 года назад
Thank you! What do you think about wait-lists as controls? They are used a lot in psychiatry to provide more interventional data.
@thomask8225
@thomask8225 5 лет назад
Thank you very much for the video!!! I have a question regarding the placebo control: How can one appraise the bias given by the side-effects of the treatment which increase the placebo-effect or boost the placebo-effect but which lacks in a placebo control? I think there were critics from Prof Kirsch regarding the RCT's of antidepressants and the lack of an "active placebo" control. Does that mean that the trials were not sufficient controlled or would that be to harsh?
@docsayedi
@docsayedi 7 лет назад
thanks Dr. Eric. Are you gonna discuss in detail on how to make sense of the results. P values and confidence intervals in particular?
@StrongMed
@StrongMed 7 лет назад
I'm sorry, but not so much in this particular series. The P value warrants a whole video just for itself. Maybe someday I'll get around to doing a biostats series (or even better, collaborate with someone more knowledgeable in biostats than myself!)
@ahmedtarek3782
@ahmedtarek3782 6 лет назад
thank you so much for this wonderful video,, very clear and straightforward and informative how can i get in touch with you doctor ?
@markolucijanic1179
@markolucijanic1179 7 лет назад
Dear Dr. Strong, what do You think of trials with "multiple primary endpoints" or co-primary endpoints like when both OS and PFS are considered co-primary endpoints in study protocol and in later publication by study authors. If statistical significance is reached for only one of those, should trial be considered positive or negative?
@StrongMed
@StrongMed 7 лет назад
Good question. As long as the co-primary endpoints were both defined as such ahead of time, and the study is adequately powered for both, then that's fine. However, progression-free survival is a poor surrogate endpoint. If a trial looked at both OS and PFS as co-primary endpoints, I would pay very little attention to PFS and focus just on OS.
@markolucijanic1179
@markolucijanic1179 7 лет назад
Thank You for the answer. I agree with Your reasoning, especially regarding OS and PFS. This way authors (sponsors) definitely increase their chance of having a positive trial.
@ahmetrmznakur
@ahmetrmznakur 4 года назад
Strong Medicine Maybe this question will be too hypothetical but I think has some point. Do you think this co-primary endpoints effectiveness still aplly when there is more endpoints than the minumum number that by chance one of them will look significant. For example roughly if there is more than 20 primary endpoints one of them will look significant by luck in the case of significant p value is less than 0.05. Thank you for your exellent videos, you are great.
@wanasyraf5648
@wanasyraf5648 Год назад
Thank you sir for the knowledge. I have requested access for the printable summary.
@StrongMed
@StrongMed Год назад
This direct link should work: drive.google.com/file/d/0B9SDUwepGWeUSVdJRzE0anpfRHM/view?usp=sharing&resourcekey=0-DqHKrdfOjiP3le4EjPdm4Q
@folumb
@folumb 7 лет назад
Hi Dr. Strong, is there an example of a poor clinical study that you might point to for a real life application of your method?
@StrongMed
@StrongMed 7 лет назад
I'd actually offer a challenge to the Strong Medicine community to come up with examples of clinical trials that don't have any flaws in either their prior assumptions, methodology, or interpretation of results. (If they are out there, I'm not sure I've read one!) In all seriousness though, this old thread on Reddit talks about a few problematic trials (ROCKET-AF, NINDS, SPRINT, RE-LY, PARADIGM-HF, etc...): www.reddit.com/r/medicine/comments/52cm08/what_are_some_landmark_clinical_trials_that/ Also, the excellent book, Ending Medical Reversal has some great discussions re: flaws in a few major trials.
@shif442
@shif442 7 лет назад
great video...any chance the that the upcoming videos will conclude the ecg videos?
@StrongMed
@StrongMed 7 лет назад
Not in the immediate future, but they are still coming eventually! Sorry for the wait.
Далее
How to Appraise a Clinical Trial - Part 3
26:13
Просмотров 14 тыс.
How to Appraise a Clinical Trial - Part 1
8:40
Просмотров 31 тыс.
Я НЕ ОЖИДАЛ ЭТОГО!!! #Shorts #Глент
00:19
На фейсконтроле 💂
09:41
Просмотров 563 тыс.
IPPCR 2019 Issues in Randomization Part 1 of 4
13:40
3. Randomised controlled trials
22:06
Просмотров 75 тыс.
What Huberman Gets Wrong About Health
8:35
Просмотров 17 тыс.
How to Identify Fake Experts
16:54
Просмотров 5 тыс.
An Approach to Shock
15:08
Просмотров 53 тыс.